• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    S

    Syneos Health

    企业
    691论文总数
    1.1万引用总数

    Syneos Health (formerly InVentiv Health Incorporated and INC Research) is a NASDAQ listed American multinational contract research organization based in Morrisville, North Carolina. The company specializes in helping companies with late-stage clinical trials. In January 2018 INC Research acquired inVentiv Health, the parent company of a subsidiary, Syneos, and the resulting company was named Syneos Health.

    论文量&引用量时间轴

    机构学者

    论文(691)

    年份
    起
    –
    止
    排序
    1HMG-CoA Reductase Inhibitors (statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results from the SHUNT-V Study.
    Robert S Rahimi,Edward Mena, Kathryn J Lucas, Michael P McRae,John Kittelson,Joanne C Imperial,Alastair D Smith,Gregory T Everson, SHUNT-V Subjects, Investigators, and Coordinators

    INTRODUCTION:Factors associated with decline of hepatic function and increase in portal-systemic shunting, which herald clinical outcome in persons with compensated cirrhosis, are poorly characterized. We used cholate challenge to evaluate the associations of liver disease etiology, concomitant diabetes, and maintenance drug therapy, with the degree of hepatic dysfunction and portal-systemic shunting. METHODS:In the SHUNT-V study, there were 255 subjects with compensated (Child-Pugh class A) cirrhosis who underwent cholate challenge, involving oral administration of [2,2,4,4- 2 H] cholate and measurement of its serum concentrations at 20 and 60 minutes. Test outputs included a disease severity index (DSI) to assess global liver function and SHUNT% to assess portal systemic shunting. RESULTS:Eighty-seven percent of subjects were overweight, 65% were obese, 48% had metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), 51% had type 2 diabetes mellitus, 49% were taking anti-diabetic drugs, and 45% were taking lipid-lowering drugs. Laboratory values and clinical scores of MASLD/MASH subjects were similar to subjects with other etiologies for liver disease. In univariable regression, MASLD/MASH, diabetes mellitus, metformin, and statins were associated with lower DSI and SHUNT%. In multivariable regression, lower DSI was attributable to statins ( P = 0.0354) and metformin ( P = 0.0561). The combined use of lipid-lowering and anti-diabetic drugs, compared with no use, was associated with 19% reduction in DSI. CONCLUSION:Concomitant use of statins alone or in combination with metformin was independently associated with preserved hepatic function (DSI) and reduced portal-systemic shunting (SHUNT%).

    2026Clinical and translational gastroenterology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Evaluating the Relationship Between the 4-Item Migraine Interictal Burden Scale and Other Patient-Reported Outcome Measures: a Post Hoc Analysis from a Phase 3 Migraine Prevention Study
    Christian Lampl,Richard B Lipton,Sarah Lipsius,Janet H Ford,Grazia Dell'Agnello,Lars Viktrup,Dawn C Buse

    BackgroundPeople with migraine report reduced health-related quality of life during ictal and interictal phases. However, most patient-reported outcome measures (PROMs) focus on impact during migraine episodes (ictal) or globally (both ictal and interictal), potentially neglecting interictal burden. This exploratory analysis evaluated correlations between the 4-item Migraine Interictal Burden Scale (MIBS-4) total score and other PROMs in people with migraine.MethodsA post hoc analysis was conducted using participant data from a galcanezumab phase 3, placebo-controlled, 3-month study, followed by a 3-month open-label extension in participants with prior treatment failures. Correlations were assessed between baseline MIBS-4 and disease characteristics, baseline MIBS-4 and demographics, and MIBS-4 and other PROMs/monthly migraine headache days at baseline and at Month (M) 6, using Spearman’s rank correlation coefficient (rs).ResultsA total of 462 participants were included (mean age: 45.8 years); 85.9% were female, 58.2% had episodic migraine and 41.8% had chronic migraine. At baseline, highest correlations with MIBS-4 were observed for Migraine Specific Quality of Life Questionnaire (MSQ)-total score, MSQ-Emotional Function (MSQ-EF), and the Patient Health Questionnaire (PHQ-9) score, which measures depressive symptoms (all p < 0.001). Correlation analysis between MIBS-4 and MSQ-total score revealed moderate correlation at baseline (rs:–0.53) that transitioned to moderate-high at M6 (rs:–0.70). MIBS-4 was moderately correlated with PHQ-9 score at baseline (rs:0.55) and M6 (rs:0.55). The Migraine Disability Assessment score transitioned from moderate-low correlation at baseline (rs:0.41) to moderate at M6 (rs: 0.53) and Generalized Anxiety Disorder score had moderate-low correlation at both time points (rs:0.42–0.47). MIBS-4 had moderate-negligible correlation with monthly migraine headache days at baseline (rs:0.21) and low correlation at Month 6 (rs:0.32).ConclusionInterictal burden, as assessed by MIBS-4, was moderately correlated with PROMs like MSQ, PHQ-9, and MIDAS, but moderate-negligible to low correlation was observed with monthly migraine headache days. These results indicate that interictal burden is a unique construct that is correlated with, but not fully captured by, other measures and should be considered when managing people with migraine.Clinical trial registrationClinicalTrials.gov identifier NCT03559257.

    2026Frontiers in neurology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Outlier-robust Copula Regression for Bivariate Continuous Proportions: an Application to Cushion Plant Vitality
    Divan A. Burger,Janet van Niekerk,Peter C. le Roux, Morgan J. Raath-Krüger

    Continuous proportions measured on the same experimental unit often pose two challenges: influential interior extremes that inflate variance beyond the beta ceiling and residual dependence that invalidates independent-margin models. We introduce a Bayesian copula modeling approach that combines rectangular-beta margins, which temper influential interior extremes by reallocating mass from the peak to a uniform component, with a single-parameter copula to capture concordance. Gaussian, Gumbel, and Clayton copula families are fitted, and log marginal likelihoods are obtained via bridge sampling to guide model selection. Applied to two surveys 13 years apart (2003 and 2016) of Azorella selago cushion plants on sub-Antarctic Marion Island, the copula models outperform independence baselines in explaining percent dead stem cover. Accounting for between-year dependence reveals a positive west-slope effect and weakens the cushion size effect. Simulation results show negligible bias and near-nominal 95

    2026Journal of Agricultural, Biological and Environmental Statistics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Long-term Survival with Lisocabtagene Maraleucel in Second-Line Large B-cell Lymphoma from TRANSFORM
    Manali Kamdar,Scott R Solomon,Jon Arnason,Patrick B Johnston,Bertram Glass,Veronika Bachanova,Sami Ibrahimi,Stephan Mielke,Pim Mutsaers, Francisco Hernandez-Ilizaliturri,Koji Izutsu,Franck Morschhauser,
    2026Blood advances(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Evaluating the Patterns of Use and Safety of Lenalidomide Treatment in Myelodysplastic Syndromes: a European, Observational Multi-Registry Study.
    Iris Kim, Aidan Makwana, Victoria Ezenma, Stefania Navarcikova, Muskan Mittal, Quinn Ho, Hannah Borda, Stefan Kaehler

    Background: Lenalidomide is an immunomodulatory agent thought to inhibit the growth of del(5q) haematopoietic progenitors in myelodysplastic syndromes (MDS) that was approved for use in Europe for certain forms of these conditions in 2013.Objectives: This study aimed to identify the distribution of lenalidomide treatment and safety outcomes in patients with MDS in Europe among those treated within (on-label) and outside (off-label) of the European Commission-approved indication.Design: This observational, retrospective study of prospectively collected disease registry data (13 June 2013 to 1 May 2023) summarised lenalidomide treatment patterns and safety outcomes by on- and off-label treatment in 11 European countries.Methods: Safety outcomes included progression to acute myeloid leukaemia (AML), second primary malignancies (SPMs), adverse events (AEs) and all-cause mortality. Hazard ratios (HRs) and 95% CI were reported for progression to AML comparing on- to off-label treatment.Results: Among 523 qualifying patients, more were prescribed lenalidomide off-label (n = 345) than on-label (n = 157); label status was unknown in 21 patients prescribed lenalidomide. Progression to AML occurred in 10.2% of on-label patients and 13.0% of off-label patients (HR: 0.9; 95% CI: 0.4, 1.7). Solid tumours were the most common SPM (7.0% on-label, 1.7% off-label). Neutropenia (38.9% on-label, 33.3% off-label) and thrombocytopenia (36.9% on-label, 28.1% off-label) were the most common AEs. Death occurred in 53 on-label and 75 off-label patients. The most common causes of death were unknown (19.1% on-label, 4.3% off-label) or due to AML (3.2% on-label, 6.1% off-label).Conclusion: Analysis of real-world registry data indicated that off-label lenalidomide use in patients treated for MDS was common. Across the registries studied, the overall incidence of safety events of lenalidomide in patients with MDS was consistent in both on-label and off-label use, highlighting the importance of researching off-label use of lenalidomide in MDS.Trial registration: This study was registered with the EU Post-Authorisation Studies (PAS) Register: EUPAS22604.

    2026Therapeutic advances in drug safety(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 691 篇论文

    合作机构(100)

    礼来公司合作论文 131
    辉瑞合作论文 52
    百时美施贵宝公司合作论文 37
    葛兰素史克合作论文 21
    宾夕法尼亚大学合作论文 19
    华盛顿大学合作论文 17
    阿尔伯塔大学合作论文 16
    勃林格殷格翰制药合作论文 15
    基因泰克合作论文 13
    俄勒冈健康与科学大学合作论文 13

    机构统计